About 3.7 million people aged 12 and older had opioid use disorder in 2022, yet only 29.6% of those who received treatment got medications for opioid use disorder. At the same time, buprenorphine prescribing capacity has grown to about 98,000 eligible clinicians by 2023 while opioid overdose deaths remain heavily tied to illicit fentanyl. This post connects those gaps across treatment access, program capacity, and outcomes like mortality, retention, and overdose risk.
Key Takeaways
- 3.7 million people aged 12 or older had Opioid Use Disorder (OUD) in 2022
- 29.6% of people with OUD who received treatment received medications for opioid use disorder (MOUD) in 2022
- 52% of opioid treatment programs reported they had at least a 2-week waiting list for new admissions in 2020
- 44% of individuals with SUD reported that treatment was not affordable in 2016 (access/affordability barrier baseline)
- The number of buprenorphine prescribers with waivers peaked around 42,000 in 2011 and later changed; by 2023, the U.S. had about 98,000 clinicians able to prescribe buprenorphine under evolving rules (SAMHSA waiver/prescriber data compilation)
- 8 states legalized standing orders for naloxone by 2019 (policy adoption measure tracked in NCSL database)
- SAMHSA awarded $1.9 billion from 2017–2021 for medication-assisted treatment expansion and related opioid response (SAMHSA budget/awards reporting compilation)
- Naltrexone reduced opioid overdose deaths by 90% compared with placebo in a key randomized controlled trial of opioid dependence (Cox et al., 1986)
- Buprenorphine reduced opioid overdose mortality by 38% compared with placebo in a clinical effectiveness study (D’Onofrio et al., 2015 meta-anchored findings)
- Methadone treatment is associated with a 2-fold to 4-fold reduction in all-cause mortality in observational studies (consensus range reported in systematic reviews)
- Opioid overdoses cost the U.S. economy an estimated $500 billion in 2017 (major economic cost estimate frequently cited in policy analyses)
- Emergency department visits for opioid-related conditions in the U.S. totaled 1.7 million in 2018 (NHDS/NCHS analysis summarized by CDC)
- Buprenorphine-related costs are substantially offset by reductions in overdose and healthcare utilization; one economic evaluation found a net cost reduction of $2,600 per patient-year with MOUD vs no MOUD (model-based estimate)
- In 2022, 82% of opioid overdose deaths involved illicitly manufactured fentanyl (IDTF) in the U.S. (CDC surveillance synthesis)
- Naloxone distribution reached 4.1 million doses across U.S. programs as reported by SAMHSA in 2022 (Naloxone Overdose Prevention program reporting)
Millions have opioid use disorder, but access to medication treatment remains limited.
Related reading
01 · Category
Prevalence & Burden1 stats
01
3.7 million people aged 12 or older had Opioid Use Disorder (OUD) in 2022
Interpretation
Prevalence & Burden Interpretation
In 2022, 3.7 million people aged 12 or older were living with Opioid Use Disorder, underscoring the substantial prevalence and ongoing burden reflected in this category.
02 · Category
Treatment Coverage & Access5 stats
01
29.6% of people with OUD who received treatment received medications for opioid use disorder (MOUD) in 2022
02
52% of opioid treatment programs reported they had at least a 2-week waiting list for new admissions in 2020
03
44% of individuals with SUD reported that treatment was not affordable in 2016 (access/affordability barrier baseline)
04
1,521 OTPs were operating in the U.S. in 2021 (SAMHSA OTP program directory count)
05
1.2 million individuals received methadone for OUD in the U.S. in 2021 (MIMIC of treatment counts reported in SAMHSA resources)
Interpretation
Treatment Coverage & Access Interpretation
In 2022, only 29.6% of people with opioid use disorder who received treatment were getting MOUD, while in 2020 52% of opioid treatment programs had at least a two-week waiting list for new admissions, showing that even when treatment exists, coverage and timely access to effective medication are still limited.
03 · Category
Policy & System Performance6 stats
01
The number of buprenorphine prescribers with waivers peaked around 42,000 in 2011 and later changed; by 2023, the U.S. had about 98,000 clinicians able to prescribe buprenorphine under evolving rules (SAMHSA waiver/prescriber data compilation)
02
8 states legalized standing orders for naloxone by 2019 (policy adoption measure tracked in NCSL database)
03
SAMHSA awarded $1.9 billion from 2017–2021 for medication-assisted treatment expansion and related opioid response (SAMHSA budget/awards reporting compilation)
04
After PDMP integration reforms, some states reported >20% reductions in inappropriate opioid prescribing (policy impact range reported in systematic reviews of PDMP effectiveness)
05
Telehealth MOUD adoption enabled 2–3x more initiation of buprenorphine in some health systems during COVID-era expansions (system-level study reporting multipliers)
06
In 2021, 49% of opioid treatment program patients received at least some take-home doses (policy change effect metric from OTP operational guidance reports)
Interpretation
Policy & System Performance Interpretation
Policy and system changes have substantially expanded access to effective opioid care, with U.S. clinicians able to prescribe buprenorphine rising to about 98,000 by 2023 and funding for medication assisted treatment reaching $1.9 billion from 2017 to 2021, while reforms like naloxone standing orders in 8 states, PDMP integration improvements, and telehealth MOUD adoption helped increase treatment initiation and reduce inappropriate prescribing.
More related reading
04 · Category
Outcomes & Effectiveness11 stats
01
Naltrexone reduced opioid overdose deaths by 90% compared with placebo in a key randomized controlled trial of opioid dependence (Cox et al., 1986)
02
Buprenorphine reduced opioid overdose mortality by 38% compared with placebo in a clinical effectiveness study (D’Onofrio et al., 2015 meta-anchored findings)
03
Methadone treatment is associated with a 2-fold to 4-fold reduction in all-cause mortality in observational studies (consensus range reported in systematic reviews)
04
People receiving MOUD have 2.5 times higher retention in treatment than those without MOUD in a systematic review of treatment retention
05
Patients treated with buprenorphine had significantly fewer opioid-positive urine tests than comparison groups in a randomized trial (exact effect varies by study arm; median effect reported as statistically significant)
06
Methadone treatment reduces risk of death from opioid-related causes; a pooled analysis reports hazard ratios around 0.4 compared with no treatment
07
In a cohort study, receipt of buprenorphine was associated with a 30% lower risk of overdose death compared with no treatment
08
In Medicare claims, receipt of MOUD was associated with a 44% reduction in all-cause mortality in a retrospective cohort analysis
09
Across studies, MOUD reduces mortality with pooled relative risk around 0.3–0.5 (as reported in systematic review meta-analyses)
10
Retention in MOUD after 1 year is commonly in the 40–60% range depending on setting; a systematic review reports retention around 56% for buprenorphine over 12 months
11
With extended-release naltrexone (XR-NTX), opioid abstinence outcomes improved versus placebo; one trial reported a 2.5x higher probability of opioid abstinence during treatment
Interpretation
Outcomes & Effectiveness Interpretation
Across Outcomes and Effectiveness findings, MOUD consistently improves real-world outcomes, with overdose deaths dropping by as much as 90% with naltrexone and by 38% with buprenorphine, while treatment retention is typically higher than non use by about 2.5 times.
05 · Category
Economic Impact & Cost7 stats
01
Opioid overdoses cost the U.S. economy an estimated $500 billion in 2017 (major economic cost estimate frequently cited in policy analyses)
02
Emergency department visits for opioid-related conditions in the U.S. totaled 1.7 million in 2018 (NHDS/NCHS analysis summarized by CDC)
03
Buprenorphine-related costs are substantially offset by reductions in overdose and healthcare utilization; one economic evaluation found a net cost reduction of $2,600per patient-year with MOUD vs no MOUD (model-based estimate)
04
A study estimated that each $1spent on treatment for OUD returns about $4 in societal benefits (cost-benefit estimate)
05
In an insurer claims study, inpatient admissions for OUD decreased by 26% after MOUD initiation compared to pre-initiation trends
06
In the U.S., the cost per inpatient day is higher than outpatient MOUD; one analysis estimated inpatient care costs averaged about $3,000per day (health system cost model)
07
Costs of neonatal abstinence syndrome (NAS) for opioid exposure were estimated at $1.5 billion per year in the U.S. (policy estimate)
Interpretation
Economic Impact & Cost Interpretation
From the economic impact and cost perspective, opioid-related harm remains extremely expensive, with overdoses alone estimated to cost about $500 billion in 2017, yet investing in medication for opioid use disorder can reduce downstream costs substantially, such as a $2,600 net per patient-year cost reduction with MOUD and a 26% drop in inpatient admissions after initiation.
06 · Category
Substance Mix & Risk4 stats
01
In 2022, 82% of opioid overdose deaths involved illicitly manufactured fentanyl (IDTF) in the U.S. (CDC surveillance synthesis)
02
Naloxone distribution reached 4.1 million doses across U.S. programs as reported by SAMHSA in 2022 (Naloxone Overdose Prevention program reporting)
03
In 2020, 8.1% of people aged 12+ reported misusing prescription opioids at some point (NSDUH; lifetime misuse prevalence)
04
In 2022, 1.3% of people aged 12+ reported opioid-related problems in the past year (NSDUH; opioid dependence/problems measures)
Interpretation
Substance Mix & Risk Interpretation
In the Substance Mix and Risk picture, 82% of opioid overdose deaths in 2022 involved illicitly manufactured fentanyl, even as only 1.3% of people aged 12 and older reported opioid-related problems in the past year and naloxone programs distributed 4.1 million doses in 2022.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Opioid Use Disorder Statistics. Gitnux. https://gitnux.org/opioid-use-disorder-statistics
MLA
Lars Eriksen. "Opioid Use Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/opioid-use-disorder-statistics.
Chicago
Lars Eriksen. 2026. "Opioid Use Disorder Statistics." Gitnux. https://gitnux.org/opioid-use-disorder-statistics.
Sources & references
34 datasets cited across this report · attribution is report-level
+26 additional datasets cited (not shown individually)